Covid-19: NZ company secures $3.3m for homegrown vaccine - (The New Zealand Herald via NewsPoints Desk)

  • A New Zealand company has secured $3.3 million in private funding to develop a COVID-19 vaccine, The New Zealand Herald reported on Sunday.

  • The COVID-19 Vaccine Corporation (CVC), set up in May, has formed collaborations with the University of Auckland, Callaghan Innovation, and research institute Scion, in an effort to independently develop a coronavirus agent.

  • CVC plans to complete its clinical trial of the new vaccine by the end of next year, which will cost around $8 million.

  • CEO Robert Feldman said that "our mission is to produce a superior vaccine that unlike those first off the block, is not created in a rush to reach the market."

  • "We are taking painstaking measures that are designed to make our vaccine generate an improved response rate while being cost-efficient to produce," he added.

  • The vaccine differs from other candidates for its unique biobead technology that it licensed from New Zealand company Polybatics.

To read more NewsPoints articles, click here.

Reference Articles